Zibotentan

  • ZD4054

Cytostatic

Endothelin A receptor antagonist

Template: Infobox chemical / molecular formula search available

Zibotentan is a potential oral appliqued cytostatic drug for the treatment of hormone-refractory prostate cancer. Currently, it is in Phase 3 clinical trials.

Zibotentan developed by the British pharmaceutical company AstraZeneca. Medicinally the ethanolamine salt is used.

Pharmacology

Mechanism of Action

Zibotentan is a selective endothelin -A receptor antagonist. Its plasma half-life is 8 hours and the plasma protein binding of 73.8 %.

836824
de